OMERS ADMINISTRATION Corp Trims Stock Holdings in Royalty Pharma plc (NASDAQ:RPRX)

OMERS ADMINISTRATION Corp cut its position in shares of Royalty Pharma plc (NASDAQ:RPRX - Free Report) by 29.4% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 57,208 shares of the biopharmaceutical company's stock after selling 23,804 shares during the period. OMERS ADMINISTRATION Corp's holdings in Royalty Pharma were worth $1,459,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its holdings in Royalty Pharma by 25.2% during the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 66,501 shares of the biopharmaceutical company's stock valued at $1,696,000 after purchasing an additional 13,376 shares in the last quarter. Ethic Inc. boosted its holdings in Royalty Pharma by 132.6% in the 4th quarter. Ethic Inc. now owns 20,342 shares of the biopharmaceutical company's stock valued at $519,000 after purchasing an additional 11,597 shares during the last quarter. D. E. Shaw & Co. Inc. increased its stake in Royalty Pharma by 24.6% during the fourth quarter. D. E. Shaw & Co. Inc. now owns 1,161,304 shares of the biopharmaceutical company's stock worth $29,625,000 after acquiring an additional 228,964 shares during the last quarter. Deutsche Bank AG boosted its stake in Royalty Pharma by 36.2% during the fourth quarter. Deutsche Bank AG now owns 3,189,964 shares of the biopharmaceutical company's stock worth $81,376,000 after buying an additional 847,704 shares during the period. Finally, Corton Capital Inc. acquired a new stake in Royalty Pharma in the 4th quarter valued at approximately $278,000. Institutional investors and hedge funds own 54.35% of the company's stock.

Royalty Pharma Stock Up 0.7%

RPRX stock traded up $0.23 during midday trading on Monday, reaching $34.25. 3,675,868 shares of the company were exchanged, compared to its average volume of 3,436,354. The company has a market cap of $19.74 billion, a price-to-earnings ratio of 23.62, a price-to-earnings-growth ratio of 2.31 and a beta of 0.49. The company has a debt-to-equity ratio of 0.64, a quick ratio of 1.44 and a current ratio of 1.44. Royalty Pharma plc has a 1-year low of $24.05 and a 1-year high of $34.52. The stock's 50-day simple moving average is $32.39 and its 200 day simple moving average is $30.01.

Royalty Pharma (NASDAQ:RPRX - Get Free Report) last released its quarterly earnings results on Thursday, May 8th. The biopharmaceutical company reported $1.06 EPS for the quarter, beating the consensus estimate of $0.99 by $0.07. Royalty Pharma had a net margin of 37.94% and a return on equity of 24.40%. The firm had revenue of $839.00 million during the quarter, compared to the consensus estimate of $724.69 million. On average, equities analysts forecast that Royalty Pharma plc will post 4.49 earnings per share for the current year.

Royalty Pharma Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 10th. Investors of record on Friday, May 16th will be paid a $0.22 dividend. This represents a $0.88 annualized dividend and a dividend yield of 2.57%. The ex-dividend date of this dividend is Friday, May 16th. Royalty Pharma's dividend payout ratio (DPR) is 47.57%.

Analyst Upgrades and Downgrades

RPRX has been the subject of several recent research reports. StockNews.com raised shares of Royalty Pharma from a "hold" rating to a "buy" rating in a research report on Monday, May 12th. Citigroup reiterated a "buy" rating on shares of Royalty Pharma in a report on Friday, March 28th. Finally, Morgan Stanley began coverage on Royalty Pharma in a report on Friday. They set an "overweight" rating and a $51.00 price target on the stock. One analyst has rated the stock with a hold rating, four have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of "Buy" and a consensus target price of $42.50.

Royalty Pharma Profile

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.